Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human TRAIL/TNFSF10 Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 15 publications
Supplier: R&D Systems MAB375500
This item is not returnable.
View return policy
Description
TRAIL/TNFSF10 Monoclonal specifically detects TRAIL/TNFSF10 in Human samples. It is validated for Immunohistochemistry, Neutralization.Specifications
TRAIL/TNFSF10 | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
Apo-2 ligand, APO2L, Apo-2Ltumor necrosis factor (ligand) family, member 10, APO2Ltumor necrosis factor apoptosis-inducing ligand splice variant delta, CD253, CD253 antigen, Protein TRAIL, TL2, TNF-related apoptosis-inducing ligand, TNFSF10, TRAILTNF-related apoptosis inducing ligand TRAIL, tumor necrosis factor (ligand) superfamily, member 10, tumor necrosis factor ligand superfamily member 10 | |
Mouse | |
Protein A or G purified from ascites | |
RUO | |
8743 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Immunohistochemistry, Neutralization | |
75411 | |
Immunohistochemistry 8-25 ug/mL, Neutralization 2-8 ng/mL | |
P50591 | |
TNFSF10 | |
Mouse myeloma cell line NS0-derived recombinant human TRAIL/TNFSF10 Thr95-Gly281 Accession # P50591 | |
500 μg | |
Primary | |
Detects human TRAIL/TNFSF10 in direct ELISAs. | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction